Home > Riviste > Minerva Gastroenterologica e Dietologica > Fascicoli precedenti > Minerva Gastroenterologica e Dietologica 2018 December;64(4) > Minerva Gastroenterologica e Dietologica 2018 December;64(4):323-32

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

SPECIAL ARTICLE   

Minerva Gastroenterologica e Dietologica 2018 December;64(4):323-32

DOI: 10.23736/S1121-421X.18.02465-0

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Gastroenterology today: between certainties and news

Rinaldo PELLICANO 1, Davide G. RIBALDONE 1, 2 , Marco ASTEGIANO 1, Luca DUGHERA 3, Edda BATTAGLIA 4, Anna MORGANDO 1, Arrigo ARRIGONI 1, Mauro SPANDRE 5, Mario GRASSINI 4, Giorgio M. SARACCO 1, 2, Francis MÉGRAUD 6

1 Unit of Gastroenterology, Molinette Hospital, Turin, Italy; 2 Department of Medical Sciences, University of Turin, Turin, Italy; 3 Unit of Digestive Motility and Endoscopy, Department of Medicine, Città della Salute e della Scienza, Turin, Italy; 4 Unit of Gastroenterology and Endoscopy, Cardinal Massaia Hospital, Asti, Italy; 5 Unit of Gastroenterology, San Giovanni Bosco, Martini and Maria Vittoria Hospitals, Turin, Italy; 6 Department of Bacteriology, INSERM U1053, University of Bordeaux, Bordeaux, France


PDF


This special article reports on two crucial issues discussed during a meeting. The first was the updated management of Helicobacter pylori (H. pylori) infection. This was approached taking into account the recent European Guidelines, with a focus on novelties in treatment. In particular, considering the increasing H. pylori antibiotic resistance to clarithromycin, in countries with a high clarithromycin resistance rate, the bismuth-containing quadruple therapies should be preferred. The new formulation, with bismuth, metronidazole, and tetracycline contained in a single capsule (three-in-one), has shown exciting results both in naive and in non-responder patients. Levofloxacin- and rifabutin-containing triple therapies should be proposed to patients who experienced H. pylori treatment failures. Another key message on H. pylori management was that, after one or more failures, standard antimicrobial susceptibility testing should be considered before prescribing a further treatment. The second issue concerned the novelties on dysbiosis of intestinal microbiota and its clinical consequences. Among the latter, the focus was on both constipation-predominant irritable bowel syndrome (IBS-C) and microscopic colitis. Since the number of microorganisms inhabiting the gastrointestinal (GI) tract is estimated to be about 10 times higher than that of human cells, it is not surprising to foresee the clinical consequences of dysbiosis. However, to date the role of dysbiosis in IBS-C and in microscopic colitis is poorly known and major efforts are needed to understand if manipulating microbiota could improve the treatment of these and other diseases both within and outside the GI tract. At a meeting held in Turin, Italy, on May 27, 2017 two crucial issues of modern gastroenterology were discussed: the updated management of Helicobacter pylori (H. pylori) infection and the novelties regarding the dysbiosis of intestinal microbiota and its clinical consequences. Among the latter, a focus was made on both constipation-predominant irritable bowel syndrome (IBS-C) and microscopic colitis. In this special article we report the most recent salient advances discussed during this meeting.


KEY WORDS: Colitis - Helicobacter pylori - Irritable bowel syndrome - Gastrointestinal microbiome

inizio pagina